Cargando…
OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer
Due to the poor metabolic conditions fomenting the emergence of the Warburg effect (WE) phenotype, abnormal glycometabolism has become a unique and fundamental research topic in the field of tumor biology. Moreover, hyperglycemia and hyperinsulinism are associated with poor outcomes in patients with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138908/ https://www.ncbi.nlm.nih.gov/pubmed/37108300 http://dx.doi.org/10.3390/ijms24087136 |
_version_ | 1785032818680659968 |
---|---|
author | Wang, Kexin Li, Qiuzi Fan, Yufeng Fang, Pingping Zhou, Haibing Huang, Jian |
author_facet | Wang, Kexin Li, Qiuzi Fan, Yufeng Fang, Pingping Zhou, Haibing Huang, Jian |
author_sort | Wang, Kexin |
collection | PubMed |
description | Due to the poor metabolic conditions fomenting the emergence of the Warburg effect (WE) phenotype, abnormal glycometabolism has become a unique and fundamental research topic in the field of tumor biology. Moreover, hyperglycemia and hyperinsulinism are associated with poor outcomes in patients with breast cancer. However, there are a few studies on anticancer drugs targeting glycometabolism in breast cancer. We hypothesized that Oxabicycloheptene sulfonate (OBHS), a class of compounds that function as selective estrogen receptor modulators, may hold potential in a therapy for breast cancer glycometabolism. Here, we evaluated concentrations of glucose, glucose transporters, lactate, 40 metabolic intermediates, and glycolytic enzymes using an enzyme-linked immunosorbent assay, Western blotting, and targeted metabolomic analysis in, in vitro and in vivo breast cancer models. OBHS significantly inhibited the expression of glucose transporter 1 (GLUT1) via PI3K/Akt signaling pathway to suppress breast cancer progression and proliferation. Following an investigation of the modulatory effect of OBHS on breast cancer cells, we found that OBHS suppressed the glucose phosphorylation and oxidative phosphorylation of glycolytic enzymes, leading to the decreased biological synthesis of ATP. This study was novel in highlighting the role of OBHS in the remodeling of tumor glycometabolism in breast cancer, and this is worth further investigation of breast cancer in clinical trials. |
format | Online Article Text |
id | pubmed-10138908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101389082023-04-28 OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer Wang, Kexin Li, Qiuzi Fan, Yufeng Fang, Pingping Zhou, Haibing Huang, Jian Int J Mol Sci Article Due to the poor metabolic conditions fomenting the emergence of the Warburg effect (WE) phenotype, abnormal glycometabolism has become a unique and fundamental research topic in the field of tumor biology. Moreover, hyperglycemia and hyperinsulinism are associated with poor outcomes in patients with breast cancer. However, there are a few studies on anticancer drugs targeting glycometabolism in breast cancer. We hypothesized that Oxabicycloheptene sulfonate (OBHS), a class of compounds that function as selective estrogen receptor modulators, may hold potential in a therapy for breast cancer glycometabolism. Here, we evaluated concentrations of glucose, glucose transporters, lactate, 40 metabolic intermediates, and glycolytic enzymes using an enzyme-linked immunosorbent assay, Western blotting, and targeted metabolomic analysis in, in vitro and in vivo breast cancer models. OBHS significantly inhibited the expression of glucose transporter 1 (GLUT1) via PI3K/Akt signaling pathway to suppress breast cancer progression and proliferation. Following an investigation of the modulatory effect of OBHS on breast cancer cells, we found that OBHS suppressed the glucose phosphorylation and oxidative phosphorylation of glycolytic enzymes, leading to the decreased biological synthesis of ATP. This study was novel in highlighting the role of OBHS in the remodeling of tumor glycometabolism in breast cancer, and this is worth further investigation of breast cancer in clinical trials. MDPI 2023-04-12 /pmc/articles/PMC10138908/ /pubmed/37108300 http://dx.doi.org/10.3390/ijms24087136 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Kexin Li, Qiuzi Fan, Yufeng Fang, Pingping Zhou, Haibing Huang, Jian OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title | OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title_full | OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title_fullStr | OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title_full_unstemmed | OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title_short | OBHS Drives Abnormal Glycometabolis Reprogramming via GLUT1 in Breast Cancer |
title_sort | obhs drives abnormal glycometabolis reprogramming via glut1 in breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138908/ https://www.ncbi.nlm.nih.gov/pubmed/37108300 http://dx.doi.org/10.3390/ijms24087136 |
work_keys_str_mv | AT wangkexin obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer AT liqiuzi obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer AT fanyufeng obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer AT fangpingping obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer AT zhouhaibing obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer AT huangjian obhsdrivesabnormalglycometabolisreprogrammingviaglut1inbreastcancer |